R. Michael Carruthers is a seasoned finance executive with over 25 years of experience in the biotechnology and pharmaceutical industries, specializing in financial strategy, capital raising, and operational leadership for high-growth companies. His career began in investment banking at Lehman Brothers, followed by key roles in corporate finance at Relypsa, Inc., where he contributed to the company's successful acquisition by Galenica AG in 2016. Carruthers later served as Vice President of Finance at Audentes Therapeutics, managing financial operations during a period of rapid clinical development and a $875 million acquisition by Astellas Pharma in 2020. As Chief Financial Officer at Edgewise Therapeutics Inc. from 2020 to 2023, Carruthers played a pivotal role in the company's transition to a public entity, leading its initial public offering on Nasdaq in 2021, which raised approximately $154 million. Under his leadership, Edgewise secured multiple venture financing rounds and strategic partnerships, enabling the advancement of its pipeline of precision medicines for muscle diseases, including the investigational therapy sevasemten for hypertrophic cardiomyopathy. His strategic oversight ensured robust financial health amid clinical milestones and expanded the company's cash runway to support ongoing Phase 2 and Phase 3 trials. Carruthers' achievements include driving value creation through mergers, acquisitions, and IPOs, earning him recognition as a key advisor in biotech financings. Post-Edgewise, he continues to consult for emerging life sciences firms, leveraging his expertise in SEC compliance, investor relations, and scaling operations in competitive markets.